{"id":"W4379333933","doi":"10.1200/jco.2023.41.16_suppl.4553","title":"Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Lenvatinib; Tolerability; Internal medicine; Clinical endpoint; Renal cell carcinoma; Oncology; Phases of clinical research; Adverse effect; Clear cell renal cell carcinoma; Urology; Cancer; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001488507,0.001020779,0.001416762,0.0004862293,0.0003297718,0.0008430266,0.0006099859,0.0008283195,0.0032124],"category_scores_gemma":[0.0007324911,0.0003960374,0.001060338,0.0005278051,0.0004458289,0.000890144,0.0003717889,0.001898477,0.0007862052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001079692,"about_ca_system_score_gemma":0.0014332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00151501,"about_ca_topic_score_gemma":0.00546837,"domain_scores_codex":[0.9996122,0.0002063293,0.0000261323,0.00005187561,0.00003167656,0.00007193181],"domain_scores_gemma":[0.999526,0.00007887228,0.00009827129,0.00002632364,0.00002002272,0.0002505184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7746714,0.0350717,0.01321584,0.0009886435,0.001773464,0.000331446,0.0002406976,0.002221601,0.02013971,0.0002065266,0.004770607,0.1463685],"study_design_scores_gemma":[0.5229406,0.4359532,0.03219236,0.00007202552,0.0008136161,0.0004092843,0.00006599161,0.001372661,0.001910602,0.0002336994,0.004005719,0.00003029507],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907006,0.002759259,0.0004096859,0.0004437171,0.00007617414,0.001788562,0.001294789,0.00008813303,0.002439126],"genre_scores_gemma":[0.9911349,0.001867673,0.001299785,0.0008029328,0.0001539446,0.001219812,0.001940952,0.00002336691,0.001556619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0032124,"threshold_uncertainty_score":0.01074654,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06792469037048972,"score_gpt":0.4135502440189556,"score_spread":0.3456255536484659,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}